News

DSN asks industry to shape #DSNIndustryIssues discussion

BY DSN STAFF

NEW YORK — Drug Store News has lined up a high-caliber roster of retail executives for the 16th annual DSN Industry Issues Summit conference, Dec. 3 at Manhattan’s historic New York Athletic Club.

And for the first time in the event’s history, DSN is issuing an open-call to the industry for discussion points.

The day-long event — which has emerged as an important day on chain pharmacy’s holiday industry week calendar — features exclusive retailer roundtable discussions around three critical areas of the business, including emerging new healthcare technologies, diabetes and chronic care and driving front-end growth.

HELP SHAPE THE DISCUSSION

Drug Store News has also announced a first in the 16-year history of the program — an open call to DrugStoreNews.com users for suggested topics and areas of discussion for our panelists. Comment below and tell us what issues and questions you want us to explore on Dec. 3. Our moderators will pick the best of the best to include in the discussion.

FOLLOW US ON TWITTER

Follow the discussion (@DrugStoreNews) live on Twitter using #DSNIndustryIssues.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

C.QUINN says:
Nov-11-2014 07:57 pm

Many retail pharmacy organizations are evaluating joining Patient Safety Organizations (PSOs) for the Federal legal protection they provide. We've seen large retailers successfully defend themselves in the court systems potentially avoiding massive fines and/or lawsuits. This is something that's been mandated in the acute care space for hospitals (above 50 beds) in 2017 - is this something your organization has looked at and/or considered?

C.QUINN says:
Nov-11-2014 07:53 pm

Given the increased govern mental regulations (mandatory reporting, collection of core measures etc) we are seeing in the acute care space many are anticipating a trickle-down effect to retail pharmacy and for similar types of information around adverse event data collection, HIPAA breaches, and so on to eventually become mandated in this space as well. Is this something leaders of retail pharmacy organizations are anticipating or preparing for? Do they have in-house systems that would be upto snuff to handle this?

swiden says:
Nov-11-2014 12:27 pm

Background: The J.D. Power 2014 U.S. Pharmacy Study, released September 18, 2014, demonstrates even the briefest intervention message from a healthcare professional can have a positive impact on patient behaviors. Question: Given workflow challenges, is there a role in pharmacist intervention models for a brief encounter with the patient that provides a generically scripted disease awareness or management message, along with printed branded patient education, resulting in a larger volume of interventions?

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Actavis’ Lo Loestrin Fe birth control patent protected through 2029

BY Michael Johnsen

DUBLIN — Actavis on Thursday confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals and Amneal Pharmaceuticals' abbreviated new drug applications for generic versions of Actavis' Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets).  
 
Lo Loestrin Fe is a prescription birth control pill used for the prevention of pregnancy.  
 
As a result of the Court's ruling, Lupin and Amneal are prevented from launching their generic versions of Lo Loestrin Fe until after the '984 Patent expires on Feb. 2, 2029.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

PhRMA names VP communications

BY Michael Johnsen

WASHINGTON — The Pharmaceutical Research and Manufacturers of America earlier this week announced that Christina Stow will join the organization as VP communications, effective Oct. 27. 
 
Stow will play a key leadership role within the communications department, PhRMA noted. She will oversee a team responsible for the day-to-day activities associated with media relations, including message development, proactive media outreach, rapid response, message research and relationship-building with key reporters and influencers. Stow will report to Robert Zirkelbach, SVP communications.
 
“We are very excited that Tina is joining our communications team here at PhRMA. Her experience managing high-profile public affairs campaigns and her deep knowledge of health care issues will be invaluable to our efforts as we seek to highlight the value of biopharmaceutical innovation and improve patients’ access to medicines,” Zirkelbach said.
 
Stow comes to PhRMA from APCO Worldwide, where she was co-practice Lead of the firm’s corporate communications and issues management service group where she most recently helped design and execute communications strategies for organizations navigating the ongoing implementation of the Affordable Care Act.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?